Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd maintains a strong liquidity position, with a current ratio of 2.56 and cash and equivalents amounting to INR 105.21 billion. The company's liquidity is further supported by a low debt-to-equity ratio of 0.05, indicating minimal reliance on debt financing. The operating cash flow of INR 121.36 billion suggests robust cash generation from core operations. The company's profitability is reflected in a return on equity of 4.17% and a return on assets of 3.1%. These figures are in line with the industry's preferred metrics, which emphasize sustainable returns and efficient asset utilization. The operating income of INR 23.40 billion and net income of INR 26.55 billion indicate a healthy margin structure. Sun Pharmaceutical Industries Ltd generates revenue across multiple geographic regions, with a significant portion derived from the United States, Europe, and India. The company's revenue concentration is not disclosed in the provided data, but its global presence suggests a diversified geographic exposure. The company's growth trajectory is supported by a strong revenue base of INR 119.83 billion. While specific growth projections for the current and next fiscal years are not provided, the company's operating cash flow and capital expenditure of INR -22.02 billion suggest a balance between reinvestment and cash preservation. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and substantial cash reserves mitigate liquidity concerns. The dilution risk is also low, with no significant dilution potential identified in the basic shares outstanding. Recent events and filings do not indicate any material changes in the company's financial or operational status. Analyst estimates suggest a positive outlook, with a mean price target of INR 2,007.00 and a median price target of INR 1,990.00. The mean recommendation of 1.84, with 12 strong-buy and 16 buy ratings, further supports a favorable market sentiment.
Business. Sun Pharmaceutical Industries Ltd is a pharmaceutical company that develops, manufactures, and markets generic and branded generic formulations and APIs, primarily in the United States, Europe, and India.
Classification. Sun Pharmaceutical Industries Ltd is classified under the Pharmaceuticals industry within the Healthcare economic sector, with a classification confidence of 0.92.
- Sun Pharmaceutical Industries Ltd has a strong liquidity position with a current ratio of 2.56 and substantial cash reserves.
- The company's profitability is reflected in a return on equity of 4.17% and a return on assets of 3.1%.
- The company's low debt-to-equity ratio of 0.05 indicates minimal reliance on debt financing.
- Analysts have a positive outlook, with a mean price target of INR 2,007.00 and a median price target of INR 1,990.00.
- The company's risk assessment indicates low liquidity and dilution risks.
- --
- # RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.